Hereditary Colorectal Cancer Syndromes and Genetic Testing

1056 Words3 Pages

The adenomatous polyposis syndromes

The genetically defined adenomatous polyposis syndromes comprise familial adenomatous polyposis (FAP), MYH-associated polyposis (MAP) and the recently described condition polymerase proofreading-associated polyposis (PPAP). Clinically, theses syndromes have significant phenotypic overlap and can be challenging to distinguish.

Familial Adenomatous Polyposis (FAP)

Over 1000 different germline mutations in the tumor suppressor gene Adenomatous Polyposis Coli (APC) located on chromosome 5q21-q22 have been shown to cause FAP. FAP occurs in 1 in 10,000 individuals 1,2 . De novo mutation in APC have been described in approximately 25% of cases 3 .

Clinical presentation

Certain APC mutations have been associated with a profuse or classic form of the disease in which hundreds to thousands of polyps are observed throughout the colon in the pre-teen to mid-teenage years. This phenotype is associated with a 100% risk of CRC by the age of 39 years in the absence of prophylactic colectomy.Often mutations in exon 9 or the 5', or 3' region of the gene are associated with attenuated FAP (AFAP) which is characterized by a lower colorectal adenoma burden (< 100 polyps), which is predominant in the proximal colon, an onset in the late teenage years and a lower lifetime risk of CRC, 70% 4 .

Upper gastrointestinal tract polyposis is the most common extra-colonic manifestation of FAP. Fundic gland polyposis (FGP), with a mean of 30 fundic gland polyps, is reported in most patients with FAP. Fundic gland polyps in FAP are frequently associated with low grade foveolar dysplasia which do not require intervention5. Gastric cancer rarely has been reported to develop from fundic gland polyposis. Experts recommend...

... middle of paper ...

...The frequency of endoscopic surveillance depends on the stage of duodenal polyposis. Patients with stage IV duodenal polyposis should be referred to an experienced surgeon for consideration of a prophylactic, pylorus-preserving, pancreas sparing duodenectomy (PPPSD) 17 . Since the prevalence of small intestinal polyps increase with the degree of duodenal polyposis, some experts recommend a capsule endoscopy every 3 years for FAP patients stage III and IV and prior to undergoing duodenectomy 18 . Celecoxib at a dose of 400 mg orally twice daily induced regression of duodenal polyposis by blinded endoscopic video review in a 6-month placebo-controlled trial 19 . Patients who have undergone targeted resection of large or numerous adenomas in an attempt to downstage duodenal polyposis require surveillance at the interval warranted by their highest Spigelman stage.

Open Document